Revolution Medicines Inc (RVMD)

Feb 19, 2025, 4:05 PM EST - 3 days ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Jan 29, 2025, 4:05 PM EST - 24 days ago

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Jan 6, 2025, 4:05 PM EST - 6 weeks ago

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 4:05 PM EST - 2 months ago

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 4, 2024, 9:09 AM EST - 2 months ago

Revolution Medicines: Risky Buy On Recent Share Price Dip

Dec 4, 2024, 6:15 AM EST - 2 months ago

Top 3 Health Care Stocks That Could Blast Off In December

ELAN SHC

Dec 3, 2024, 10:38 PM EST - 2 months ago

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 2, 2024, 4:31 PM EST - 2 months ago

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Dec 2, 2024, 7:30 AM EST - 2 months ago

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Nov 27, 2024, 4:05 PM EST - 3 months ago

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Nov 6, 2024, 7:52 PM EST - 3 months ago

Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:02 PM EST - 3 months ago

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Nov 5, 2024, 9:00 AM EST - 3 months ago

Revolution Medicines to Participate in Upcoming Investor Conferences

Oct 30, 2024, 4:05 PM EDT - 4 months ago

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

Oct 25, 2024, 4:15 AM EDT - 4 months ago

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Oct 23, 2024, 6:00 AM EDT - 4 months ago

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Oct 21, 2024, 4:05 PM EDT - 4 months ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Oct 7, 2024, 9:00 AM EDT - 4 months ago

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

Aug 11, 2024, 2:00 AM EDT - 7 months ago

Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 7 months ago

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

Jul 31, 2024, 4:05 PM EDT - 7 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

Jul 16, 2024, 8:16 AM EDT - 7 months ago

Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter

AVAH FULC

Jul 11, 2024, 12:00 PM EDT - 8 months ago

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Jul 8, 2024, 4:05 PM EDT - 8 months ago

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

Jun 5, 2024, 4:05 PM EDT - 9 months ago

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 4:02 PM EDT - 10 months ago

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

May 1, 2024, 4:05 PM EDT - 10 months ago

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

Apr 9, 2024, 3:34 PM EDT - 11 months ago

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Apr 8, 2024, 11:36 AM EDT - 11 months ago

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Mar 28, 2024, 4:05 PM EDT - 11 months ago

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

Feb 26, 2024, 10:45 PM EST - 1 year ago

Revolution Medicines, Inc. (RVMD) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:05 PM EST - 1 year ago

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Feb 20, 2024, 4:05 PM EST - 1 year ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

Jan 4, 2024, 7:00 AM EST - 1 year ago

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 9, 2023, 9:10 AM EST - 1 year ago

Revolution Medicines Completes Acquisition of EQRx

Nov 8, 2023, 11:30 AM EST - 1 year ago

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

Nov 6, 2023, 8:04 PM EST - 1 year ago

Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call Transcript

Nov 6, 2023, 4:05 PM EST - 1 year ago

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

Oct 31, 2023, 4:15 PM EDT - 1 year ago

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

Oct 22, 2023, 2:30 AM EDT - 1 year ago

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

Oct 13, 2023, 11:50 AM EDT - 1 year ago

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

Oct 6, 2023, 2:26 PM EDT - 1 year ago

EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX

Oct 6, 2023, 8:26 AM EDT - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

CUTR OMGA VNRX

Oct 4, 2023, 4:05 PM EDT - 1 year ago

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

Sep 25, 2023, 3:24 PM EDT - 1 year ago

Revolution Medicines: A Big Pipeline In Need Of Big Data

Sep 25, 2023, 9:00 AM EDT - 1 year ago

Revolution Medicines' Strategic Edge In RAS-Driven Oncology

Sep 19, 2023, 7:00 AM EDT - 1 year ago

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

Aug 17, 2023, 4:05 PM EDT - 1 year ago

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins